



## **Avalanche Biotechnologies to Host Analyst and Investor Day on March 25, 2015**

March 18, 2015

MENLO PARK, Calif., March 18, 2015 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced that it will host an Analyst and Investor Day on March 25, 2015 in New York. Avalanche management will be joined by other notable ophthalmology leaders to discuss its clinical programs in development as well as advancements in next-generation technology and vision for the future.

A webcast of the presentation will be accessible under [Events & Presentations](#) in the Investors section of [www.avalanchebiotech.com](http://www.avalanchebiotech.com). Avalanche will maintain an archived replay of the webcast on its website for at least two weeks.

### **Event**

Date: March 25, 2015

Time:

Breakfast and Registration: 7:30 a.m. EDT

Program and Webcast: 8:00 a.m. – 11:30 a.m. EDT

### **Guest Speakers**

- **Jean Bennett M.D., Ph.D.**, Professor, Ophthalmology; Director, Center for Advanced Retinal and Ocular Therapeutics (CAROT), University of Pennsylvania Perelman School of Medicine
- **David Brown, M.D.**, Retina Consultants of Houston; Clinical Professor of Ophthalmology, Baylor College of Medicine
- **Jeffrey S. Heier, M.D.**, Director of Vitreoretinal Service, Ophthalmic Consultants of Boston
- **Szilárd Kiss, M.D.**, Director of Clinical Research and Associate Professor of Ophthalmology, Weill Cornell Medical College

### **About Avalanche Biotechnologies, Inc.**

Avalanche is a biopharmaceutical company committed to improving or preserving the sight of people suffering from blinding eye diseases with a clear unmet medical need. Avalanche's proprietary Ocular BioFactory™ is a platform for discovering and developing novel medicines with the potential to offer life-changing therapeutic benefit. Avalanche's lead product candidate, AVA-101, is in mid-stage clinical development for patients with wet age-related macular degeneration. For more information, please visit [www.avalanchebiotech.com](http://www.avalanchebiotech.com).

CONTACT: Investor Contact

Lauren Glaser

(650) 656-9347

[lauren@avalanchebiotech.com](mailto:lauren@avalanchebiotech.com)

Media Contact

Carolyn Wang

(415) 946-1065

[cwang@w2ogroup.com](mailto:cwang@w2ogroup.com)

[Avalanche Biotechnologies Logo](#)

Avalanche Biotechnologies, Inc.